ReviewFrontiers in aging neuroscience2014
The potential applications of Apolipoprotein E in personalized medicine.
Review in Frontiers in aging neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- What Causes Premature Coronary Artery Disease?Current atherosclerosis reports · 2024Review
- Review
- Association of DNA methylation and genetic variations of theBiomedical reports · 2022Article
- [Nutrigenetics: potentials and applications in cardiovascular diseases and associated risk factors].Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2022Article
- Personalized nutrition: A review of genotype-based nutritional supplementation.Frontiers in nutrition · 2022Review
- Analysis of Gene-Environment Interactions Related to Developmental Disorders.Frontiers in pharmacology · 2022Review
- Association between clinical symptoms and apolipoprotein A1 or apolipoprotein B levels is regulated by apolipoprotein E variant rs429358 in patients with chronic schizophrenia.Annals of general psychiatry · 2021Article
- Article
- Impact ofViruses · 2021Article
- Apolipoprotein E ε4 Allele-Based Differences in Brain Volumes Are Largely Uniform Across Late Middle Aged and Older Hispanic/Latino- and Non-Hispanic/Latino Whites Without Dementia.Frontiers in aging neuroscience · 2021Article
- Kefir peptides alleviate high-fat diet-induced atherosclerosis by attenuating macrophage accumulation and oxidative stress in ApoE knockout mice.Scientific reports · 2020Article
- Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine.Pharmacology & therapeutics · 2019Review
- The effect of apolipoprotein E polymorphism on serum metabolome - a population-based 10-year follow-up study.Scientific reports · 2019Article
- Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.JAMA neurology · 2018Observational
- Association of body mass index with amnestic and non-amnestic mild cognitive impairment risk in elderly.BMC psychiatry · 2017Article
- Apolipoprotein E4: A Risk Factor for Successful Cognitive Aging.Dementia and neurocognitive disorders · 2016Review
- Apolipoprotein E genotyping and questionnaire-based assessment of lifestyle risk factors in dyslipidemic patients with a family history of Alzheimer's disease: test development for clinical application.Metabolic brain disease · 2016Article
- Article
- Personalized biochemistry and biophysics.Biochemistry · 2015Article
- Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment.The journal of prevention of Alzheimer's disease · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Personalized medicine uses various individual characteristics to guide medical decisions. Apolipoprotein (ApoE), the most studied polymorphism in humans, has been associated with several diseases. The purpose of this review is to elucidate the potential role of ApoE polymorphisms in personalized medicine, with a specific focus on neurodegenerative diseases, by giving an overview of its influence on disease risk assessment, diagnosis, prognosis, and therapy. This review is not a systematic inventory of the literature, but rather a summary and discussion of novel, influential and promising works in the field of ApoE research that could be valuable for personalized medicine. Empirical evidence suggests that ApoE genotype informs pre-symptomatic risk for a wide variety of diseases, is valuable for the diagnosis of type III dysbetalipoproteinemia, increases risk of dementia in neurodegenerative diseases, and is associated with a poor prognosis following acute brain damage. ApoE status appears to influence the efficacy of certain drugs, outcome of clinical trials, and might also give insight into disease prevention. Assessing ApoE genotype might therefore help to guide medical decisions in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.